RCM
ONCT

Rotella Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Rotella Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-32
Closed -$66K – 682
2015
Q2 		$66K Buy
+32
New +$45.5K 0.05% 346

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Rotella Capital Management's ONCT Position: Q3 2015 in Review

Rotella Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2015, closing a stake of 32 shares — an estimated $66K sold.

Rotella Capital Management first reported a position in ONCT in Q2 2015 and held it in 1 quarter. The position peaked at $66K in Q2 2015. 38 funds tracked by Wall St. Rank hold ONCT as of Q3 2015.

  • Rotella Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 32 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $66K.
  • Rotella Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Rotella Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $66K in Q2 2015.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.